1.19
-0.05(-4.03%)
Currency In USD
Address
PMB #117, 2801 Centerville Road
Wellesley Hills, DE 19808-1609
United States of America
Phone
866 857 2596
Website
Sector
Healthcare
Industry
Biotechnology
Employees
17
First IPO Date
N/A
| Name | Title | Pay | Year Born |
| Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc | Chief Executive Officer, President & Director | 854,402 | 1977 |
| Dr. Brett Kaplan M.B.A., M.D. | Chief Operating Officer, Treasurer, Secretary & Principal Financial Officer | 583,846 | 1975 |
| Ms. Kate Hecht M.B.A. | Senior Vice President of Program Management | 0 | N/A |
| Dr. Nishi Rampal M.D. | Senior Vice President of Clinical Development | 0 | N/A |
| Ms. Janaki M. Subramanyam M.Sc. | Vice President & Head of Regulatory Affairs | 0 | N/A |
| Dr. Perrin Wilson B.S., Ph.D. | Chief Business Officer | 0 | N/A |
| Ms. Emily Pimblett CPA | Senior Vice President of Finance & Chief Accounting Officer | 0 | 1984 |
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.